According to GlobalData’s medical device pipeline database, 70 Tissue Sealants devices are in various stages of development globally. GlobalData’s report Tissue Sealants provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 29 are in active development, while the remaining 42 are in an inactive stage of development. There are 20 products in the early stages of development, and the remaining nine are in the late stages of development.

Tissue sealants serve primarily as a physical barrier to prevent leakage of fluid and/or gas from a surgical incision. They can be used to hold the flaps of internal organs together, to seal the blood vessels in case of injury/surgery or as an adjunct with hemostatic agents. Tissue sealants based on their composition can be classified as either synthetic or non-synthetic tissue sealants. The volume of tissue sealant used per procedure varies depending on the type of procedure and formulation. Thus, one unit of tissue sealant is defined as the average volume used for a single procedure. Tissue sealants may be sold in a kit consisting of a delivery device and an activating agent such as thrombin. These delivery devices and activating agents are not tracked under this segment.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Tissue Sealants pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Tissue Sealants devices. Overall, most of these Tissue Sealants pipeline devices are being developed by private entities.

Key players involved in the active development of Tissue Sealants include CR Bard, Polyganics, Cohera Medical, Sealantis, HyperBranch Medical Technology, Kuros Biosciences, GATT Technologies, Aleo BME, Baxter International and Nurami Medical.

For a complete picture of the developmental pipeline for Tissue Sealants devices, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.